Stock futures rallying this morning presumably in part because former President Trump survived the assassination attempt this weekend. 

Yesterday’s market action showcased one of its most important attributes, and that is it’s broad and diverse sector participation. 

The stock market heading into the second quarter earnings reporting season structurally sound from a technical perspective.

Rotational consolidations appear to be intensifying among a number of different sectors and themes, and I think that the major market indices could become lodged in a limited trading range over the near term. 

It is out with the old and in with the new as today marks the beginning of the 3rd quarter of 2024. And the old wasn’t so bad…the 1st half of 2024 delivered quite nicely… 

I think the quarter was quite revealing in certain ways: certainly the big highlight of the quarter was technology, and more specifically the Artificial Intelligence sub-category. 

Yesterday was a flip flop in performance from the prior day’s action; yesterday the Nasdaq rallied by 200+ points, while the Dow fell nearly 300 points — somewhat of a mirror opposite from the prior session. 

Biotechnology was a glistening theme in yesterday’s session. An FDA approval on a drug and positive test results for another drug spurred big gains in 2 of the biotech stocks, which put the focus on healthcare generally, once again. 

Some market observers are calling for a significant correction over the short run; I can see where they’re making that case from a technical perspective. 

Aggressive growth categories in the lead...